Genentech reported that satralizumab (Enspryng) reduced the risk of relapse by 68% compared to placebo in the Phase III METEOROID study in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a rare autoimmune CNS disorder that currently has no approved treatments anywhere in the world.
METEOROID is a Phase III, randomized, double-blind, placebo-controlled, multicenter trial enrolling adults and adolescents aged 12 and older with MOGAD, comparing subcutaneous satralizumab against placebo on a weight-based dosing schedule.
At 48 weeks, 87% of patients on satralizumab were relapse-free versus 67% on placebo, with the primary endpoint — time to first relapse — meeting statistical significance (p=0.0025). The annualized relapse rate fell by 66% with satralizumab (p=0.0030). Secondary endpoints showed a 79% reduction in the annualized rate of active MRI lesions across the optic nerves, brain, and spinal cord, and 73% fewer patients required rescue therapy such as steroids, plasma exchange, or intravenous immunoglobulins (p=0.0026 and p=0.0024, respectively). A 17% reduction in inpatient hospitalizations was observed but did not reach statistical significance (p=0.7528). Cross-trial comparisons are limited by differences in study design, patient populations, and endpoints.
The MOGAD data position satralizumab as the first therapy to show controlled Phase III evidence in a disease where clinicians currently rely entirely on off-label agents — rituximab, mycophenolate mofetil, azathioprine, and intravenous immunoglobulin — none of which have been validated in a randomized trial specific to this indication. The absence of any approved standard of care means that if regulatory submissions succeed, satralizumab would enter a space with no direct licensed competition.
Satralizumab is a humanized monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), suppressing downstream pro-inflammatory signaling. The mechanistic rationale in MOGAD is supported by elevated IL-6 levels in the cerebrospinal fluid and serum of affected patients, where IL-6 promotes T-cell-mediated inflammation, drives autoantibody production from plasma cells, and disrupts the blood-brain barrier. The drug was engineered using recycling antibody technology, which prolongs target engagement compared with conventional monoclonal antibody formats.